Lilly’s Zepbound (tirzepatide) got additional 6.7% weight loss

eAwaz 12 December 2023Medicine

INDIANAPOLIS – Detailed results from SURMOUNT-4, which showed Zepbound™ (tirzepatide) injection achieved superior mean percent change in body weight compared to placebo in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes, were published in The Journal of the American Medical Association (JAMA). Zepbound met the primary endpoint of mean percent change in body weight, and all key secondary endpoints …

Lilly drug slows Alzheimer’s progression

eAwaz 4 May 2023Medicine

CHICAGO – Eli Lilly and Co’s experimental Alzheimer’s drug slowed cognitive decline by 35% in a closely watched late-stage trial. The drug, donanemab, slowed progression of Alzheimer’s by 35% to 36% compared to a placebo in 1,182 people diagnosed with early-stage disease, Lilly said.